Featured News

A study from the University of Chicago has demonstrated that B-cells are required for the development of villous atrophy (intestinal damage) in celiac disease. This finding provides support for the exploration of B-cell–directed therapies for the treatment of celiac disease.

Celiac disease patients are at an increased risk, albeit small, of cancer, and the findings from these studies confirm the importance of a healthy immune system in cancer prevention. For patients with celiac disease, adhering to a strict, gluten-free diet is critical to maintaining a healthy immune system.

Researchers found higher rates of skin disease in patients with celiac disease compared to controls, including increased risks for eczema, psoriasis, urticaria, vitiligo, acne, and alopecia areata.

researchers concluded that patients with celiac disease who are infected with COVID-19 are not at higher risk of hospitalization.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.

My appointment to PCORI’s Advisory Panel on Patient Engagement has just ended. It was a productive and enlightening three-year engagement that has helped inform my ongoing service to the celiac…

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

Researchers found that roughly one-third of celiac patients reported using probiotics for perceived health benefits, despite the lack of evidence that probiotics are an effective treatment for celiac disease symptoms.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.